GoodRx Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
GoodRx Holdings, Inc. (GDRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-12-31 was $48.70M, a 44.22% decline year-over-year.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-09-30 was $97.10M, a 322.17% increase year-over-year.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-06-30 was $79.90M, a 7890.00% increase year-over-year.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2021-03-31 was $18.70M, a 1235.71% increase year-over-year.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $100.00K, a 98.75% decline from fiscal 2024.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $8.00M, a 37.93% increase from fiscal 2023.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $5.80M, a 68.13% decline from fiscal 2022.
- GoodRx Holdings, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $18.20M, a 92.55% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $8.00M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $5.80M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $18.20M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $48.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $145.80M derived: sum of 2 quarters · filed 2024-02-29 | $225.70M derived: sum of 3 quarters · filed 2024-02-29 | $244.40M 10-K · filed 2024-02-29 |
| 2021-09-30 | $97.10M 10-Q · filed 2021-11-12 | $177.00M derived: sum of 2 quarters · filed 2021-11-12 | $195.70M 10-Q · filed 2021-11-12 | $283.00M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $79.90M 10-Q · filed 2021-08-12 | $98.60M 10-Q · filed 2021-08-12 | $185.90M derived: sum of 3 quarters · filed 2023-03-01 | $208.90M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $18.70M 10-Q · filed 2021-05-14 | $106.00M derived: sum of 2 quarters · filed 2023-03-01 | $129.00M derived: sum of 3 quarters · filed 2023-03-01 | $130.00M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $87.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $110.30M derived: sum of 2 quarters · filed 2023-03-01 | $111.30M derived: sum of 3 quarters · filed 2023-03-01 | $112.70M 10-K · filed 2023-03-01 |
| 2020-09-30 | $23.00M 10-Q · filed 2021-11-12 | $24.00M derived: sum of 2 quarters · filed 2021-11-12 | $25.40M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.00M 10-Q · filed 2021-08-12 | $2.40M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.40M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | $11.10M 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $11.20M 10-K · filed 2021-03-12 |